| Company/Division name | AstraZeneca |
| Parent company | Astra Zeneca |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Total number of jobs (added or to be added): | 300 |
| Year reshoring announced: | 2025 |
| Year reshoring implemented or to be implemented: | 2029 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 1800 |
| Country(ies) from which reshored: | United Kingdom |
| City reshored to: | Frederick and Gaithersburg |
| State(s) reshored to: | MD |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | pharmaceuticals |
| What non-domestic negative factors made offshoring less attractive? | Supply chain interruption |
| What domestic positive factors made reshoring more attractive? | Government Incentives, Impact on domestic economy, Skilled workforce availability/training |
| Government Incentive dollar amount: | 10% investment match of total project costs |
